Rapid superselective high-dose cisplatin infusion with concomitant radiotherapy for squamous cell carcinoma of the nasal vestibule: a report of two cases

Abstract

Squamous cell carcinoma of the nasal vestibule (SCC-NV) is rare among head and neck malignancies. It behaves differently from cancers arising in the nasal cavity and paranasal sinuses, and skin cancer of the external nose. Prognosis is more favorable than nasal cavity tumors and less favorable than skin cancers. We experienced two cases of SCC-NV who were treated with rapid superselective high-dose cisplatin infusion with concomitant radiotherapy (RADPLAT). A 56-year-old male and a 68-year-old female with SCC-NV, classified as T4aN0M0 according to UICC and T2 according to Wang classification, were given superselective intra-arterial infusions of cisplatin, with simultaneous intravenous infusions of thiosulfate to neutralize cisplatin toxicity, together with conventional radiotherapy. In both cases, the internal maxillary artery and the facial artery were considered to be feeders of the tumor. No serious adverse events have been observed in either patient to date during follow-up of 7.3 and 5.3 years, respectively. Both patients are alive without disease and show excellent cosmetic results. RADPLAT is considered to be useful for the treatment of patients with SCC of the nasal vestibule.

Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience

“…However, we did not focus on SCC of the NC&ES in that study. As we previously reported, RADPLAT is considered to be effective for the treatment of patients with locally advanced SCC of the nasal vestibule, with excellent cosmetic results reported [5]. As for NC&ES, tumors are expected to be mainly supplied by the external carotid system, but also partially supplied by the internal carotid system, such as the anterior and posterior ethmoid arteries, particularly when the tumors arise from ethmoid sinus.…”

“…Eight patients (32%) were treated with radiotherapy and concomitant intra-arterial chemotherapy (RADPLAT). The treatment protocol for IV-CRT and RADPLAT has been described elsewhere [3][4][5][6]. …”